Osterweis Capital Management Inc. Invests $4.10 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Osterweis Capital Management acquired 50,315 shares of Arrowhead Pharmaceuticals worth approximately $4.1 million during the second quarter. Institutional investors collectively own 62.61% of ARWR.
• Analyst sentiment is broadly positive: nine analysts rate the stock a Buy, three rate it Hold, and one rates it Sell, resulting in a consensus “Moderate Buy” rating and an average price target of $97.33.
• Arrowhead reported quarterly revenue of $75.25 million, up 171% year over year and above expectations, but missed on EPS with a loss of $1.36 per share versus the expected $1.23 loss.

Osterweis Capital Management Inc. acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 50,315 shares of the biotechnology company's stock, valued at approximately $4,101,000.

Several other institutional investors have also added to or reduced their stakes in ARWR. Tsfg LLC bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $25,000. Optiver Holding B.V. raised its position in shares of Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company's stock valued at $26,000 after purchasing an additional 186 shares during the period. Versant Capital Management Inc raised its position in shares of Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 248 shares during the period. Carolina Wealth Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company's stock valued at $28,000 after buying an additional 154 shares in the last quarter. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $29,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,000 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director owned 31,600 shares of the company's stock, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the sale, the director owned 111,459 shares of the company's stock, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their position. The SEC filing for this sale provides additional information. 3.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ARWR has been the subject of a number of recent research reports. JPMorgan Chase & Co. lifted their price objective on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. B. Riley Financial increased their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Chardan Capital raised their price target on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the stock a "buy" rating in a report on Wednesday, July 22nd. Leerink Partners lifted their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a "market perform" rating in a research report on Wednesday, June 17th. Finally, Wall Street Zen raised Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 27th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $97.33.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $88.88 on Wednesday. The company's 50 day simple moving average is $83.28 and its two-hundred day simple moving average is $73.12. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $20.59 and a 1 year high of $95.49. The stock has a market capitalization of $12.52 billion, a PE ratio of -39.50 and a beta of 1.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm had revenue of $75.25 million for the quarter, compared to analysts' expectations of $44.17 million. During the same quarter last year, the firm earned ($1.26) earnings per share. The firm's revenue for the quarter was up 171.0% on a year-over-year basis. Analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source